Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular T...( ventricular tachycardia (1.1percent) an...),Health

NEXTERONE is contraindicated in patients with known hypersensitivity to any of the components of NEXTERONE, including iodine, or in patients with cardiogenic shock, marked sinus bradycardia, and second- or third-degree AV block unless a functioning pacemaker is available.

NEXTERONE is for hospital use only. NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of intravenous amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment.

For more information about NEXTERONE, including full prescribing information, visit http://www.prismpharma.com.

About Prism Pharmaceuticals

Prism Pharmaceuticals, based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. The product portfolio strategy is focused on recognizing unfulfilled opportunities in existing compounds that address current unmet medical needs with a specific focus on medication safety in the hospital environment.

Prism was started in 2004 with a founding investment from Essex Woodlands Health Ventures (http://www.ewhv.com). In 2006 Prism secured a $68M layered financing of equity from Essex combined with equity and a revenue interest agreement from Paul Capital (http://www.paulcap.com). This level of sustaining investment has enabled Prism to pursue an aggressive licensing and rapid development model resulting in the successful approval of NEXTERONE.

The worldwide rights to NEXTERONE w
'/>"/>